Brought to you by 
Poseida withdraws IPO filing, goes for $142mm Series C round instead
23 Apr 2019
Executive Summary
Poseida Therapeutics Inc. (CART treatments for cancer and gene therapies for orphan genetic diseases) raised $142mm through a Series C round. Novartis Pharma AG led with a $75mm investment, and was joined by new investors Aisling Capital Management, Pentwater Capital Management, Perceptive Advisors, and other undisclosed institutional investors, along with returning backers Malin Corp. PLC, Longitude Capital, Vivo Capital, and Boxer Capital (Tavistock). The Series C was announced concurrent with Poseida withdrawing its filing for an initial public offering. The company filed for the IPO in January, but after a series of delays and expressed interest from investors, opted to cancel the IPO and take in the Series C funds instead.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Poseida withdraws IPO filing, goes for $142mm Series C round instead
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice